Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Neoplasms, Male × elacestrant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 23 Advanced Breast Cancer 2 Sarcoma, Endometrial Stromal 1 Recurrence 1 Perivascular Epithelioid Cell Neoplasms 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Endometrial Neoplasms 1 ER+ Breast Cancer 1 Central Nervous System Neoplasms 1 Central Nervous System Diseases 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Neoplasms, Male 1 Breast Diseases 1 Breast Cancer Patients 1 Brain Neoplasms 1 Brain Diseases 1 Advanced ER+, HER2-Negative Breast Cancer 1 Adenosarcoma of the uterus 1

Interventions

Cyclophosphamide 31 Trastuzumab 30 Paclitaxel 28 Docetaxel 22 Taxes 18 Doxorubicin 18 Lapatinib 15 Radiotherapy 14 Capecitabine 14 Bevacizumab 13 Tamoxifen 12 Carboplatin 11 Filgrastim 9 sargramostim 8 Granulocyte-Macrophage Colony-Stimulating Factor 8 Chemotherapy, Adjuvant 8 exemestane 7 Vorinostat 7 Letrozole 7 Immunohistochemistry 7 Gemcitabine 7 Anastrozole 7 Albumin-Bound Paclitaxel 7 pegfilgrastim 6 Neoadjuvant Therapy 6 Magnetic Resonance Spectroscopy 6 Immunoenzyme Techniques 6 Goserelin 6 Flow Cytometry 6 Everolimus 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06492616 2026-03-27

ELEGANT

Stemline Therapeutics, Inc.

Phase 3 Recruiting

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon ⚡